LILLY ELI & CO Form 8-K June 10, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report	(Date of Earliest Event Reported):	June 9, 2005	5
Dute of Report	(Dute of Eurilest Event Reported).	June 2, 2003	,

Eli Lilly and Company

(Exact name of registrant as specified in its charter)

Indiana	001-06351	35-0470950
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)
Lilly Corporate Center, Indianapolis, Indiana		46285
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area c	ode:	317-276-2000
	Not Applicable	
Former name or f	Former address, if changed since	last report
Check the appropriate box below if the Form 8-K filing is in the following provisions:	ntended to simultaneously satisfy	the filing obligation of the registrant under any of
Written communications pursuant to Rule 425 under the Soliciting material pursuant to Rule 14a-12 under the Expression of Pre-commencement communications pursuant to Rule 1 Pre-commencement communications pursuant to Rule 1	schange Act (17 CFR 240.14a-1 4d-2(b) under the Exchange Act	2) t (17 CFR 240.14d-2(b))

Top of the Form Item 8.01. Other Events.

On June 9, 2005, Eli Lilly and Company (the "Company") announced that it had entered into an agreement in principle with plaintiffs' attorneys involved in Zyprexa® product liability litigation to settle a majority of the claims against the Company relating to the medication. The Company's press release announcing the tentative settlement is attached as Exhibit 99 to this Form 8-K.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Eli Lilly and Company

June 10, 2005 By: Thomas W. Grein

Name: Thomas W. Grein

Title: Vice President and Treasurer

Top of the Form

Exhibit Index

Exhibit No.	Description
99	Press Release